Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information. Important factors that could cause actual results to differ materially from the Company's expectations including the risks detailed from time to time in the Company's public disclosure. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. This news release contains forward-looking statements. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of integrative mental health clinics and operates a full-service contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. Net loss and comprehensive loss for the period Realized gain on disposition of marketable securities Realized gain on settlement of convertible debenture Unrealized (loss) gain of marketable securities and convertible debentures In January 2022, closed the acquisition of Arizona-based Foundations for Change, a mental health practice specialized in ketamine-assisted psychotherapy with two clinic locations in the Phoenix areaĮnrolled final cohorts and advanced to final stages of the Frontline KAP clinical pilot, a candidate for commercialization at Novamind's clinicsĪppointed Prakash Gowd, MBA, BSc Pharm, C Dir as Chief Operating OfficerĬontracted to provide clinical research services for the following clinical trials:Ī phase I clinical trial examining ketamine-assisted therapy combined with Mindfulness-Oriented Recovery Enhancement therapy to treat opioid use disorder, led by investigator Eric Garland, PhD at the University of UtahĪ phase II clinical trial investigating ketamine-assisted psychotherapy for adults with life-threatening illness, sponsored by the Ketamine Research FoundationĪ phase II clinical trial investigating an antidepressant medication for adults with major depressive disorder and post-traumatic stress disorder, sponsored by Alto Neuroscience Opened a new outpatient clinic located in downtown Salt Lake City, specialized in integrative behavioural health and services for adults with substance use disorders Unveiled a new clinic design concept to accommodate the unique requirements of psychedelic-assisted psychotherapy Novamind is focused on providing clinical research services to leading drug developers, meeting patient demand by delivering innovative, evidence-based mental healthcare and bringing to market new treatment programs such as Psychedelic Palliative Care by Novamind and Frontline KAP."įiscal Q2 2022 Operating Highlights and Subsequent EventsĪnnounced a strategic investment and advisory agreement with Bienstar Wellness to develop Latin America's first network of integrative mental health clinics Novamind CEO, Yaron Conforti, commented, "We're pleased to report record high revenue this quarter driven by continued revenue growth from existing and new clinics. All results are reported under International Financial Reporting Standards ("IFRS") and in Canadian dollars, unless otherwise specified. TORONTO, ON / ACCESSWIRE / Ma/ Novamind Inc.(CNSX:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, reported its financial results for the three and six months ended Decem("Fiscal Q2 2022"). In January 2022, successfully closed the acquisition of an Arizona-based mental health practice, adding two additional clinics, and closed a $5,000,000 institutional private placement Strong pipeline of clinical trials for psychedelics and mental health treatments Opened new outpatient clinic located in downtown Salt Lake City Record high revenue of $2,452,540, +32% over the previous quarter
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |